FAS and cancer: These results suggest that a combined pathway derived from the RTK-RAS-MAPK oncopathway and PI3K-AKT proapoptotic pathway following stimulus-dependent activation of receptors is a promising molecular target for cancer therapies; these targets also include EGF receptor family members including EGFR, ERBB2/3/4, and MET and the FAS death receptor (Figure 6D).